LANXESS Aktiengesellschaft is a specialty chemicals company that develops, manufactures, and markets chemical intermediates, additives, and modern plastics. The company's product portfolio includes iron oxide pigments, flame retardants, anti-aging agents for tires, and consumer protection products for home care and institutional cleaning. LANXESS serves end markets such as agriculture, animal care, coatings, plastics, and construction, with a presence in Europe and Asia. The company has produced iron oxide pigments since 1926 and utilizes hydrogen in large-scale industrial plants for pigment production. It offers products under brands such as Bayferrox and provides solutions for electric mobility and circular economy applications, including NIR-reflective pigments for plastic recycling.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Specialty Chemicals Homepage lanxess.com
Sector Basic Materials IR page lanxess.com/en/investors
Tags
iron oxide pigments, flame retardants, chemical intermediates, additives, consumer protection, tire protection, home care, institutional cleaning, agriculture, animal care, plastics, coatings, Bayferrox, Bayferrox 303 T
Press page —

Metrics

Valuation  
Market cap € 1.004B
Market cap (USD) $ 1.121B
P/E -1.52
PEG —
P/BV 0.23
P/S 0.18
P/OCF 3.47
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin -10.2%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -28.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 5.673B 6.366B 6.714B 8.088B 7.557B 6.104B 6.802B 7.197B 9.664B 7.699B 7.902B 8.006B 8.3B 9.094B 8.775B 7.12B 5.057B
Net profit -576M — 443M 250M 267M 885M 205M — 124M 195M 167M 44M -168M 515M 507M 381M 39M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Share price 17.62 23.58 28.37 37.7 54.5 62.76 59.82 40.2 66.29 62.35 42.68 38.46 66.27 66.27 40 59.1 —
Price performance 12m -0.25 -0.17 -0.25 -0.31 -0.13 0.05 0.49 -0.39 0.06 0.46 0.11 -0.42 0 0.66 -0.32 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

  • New product line for skin and hair care, sun protection, and decorative cosmetics

  • Premium sensory performance in both silicone-containing and silicone-free cosmetic formulations

  • Degrades faster in the environment after use

CologneOctober 26, 2026

©Kryuchka Yaroslav - stock.adobe.com

Cosmelin esters from LANXESS are readily biodegradable and developed for use in both silicone-containing and silicon-free cosmetic formulations

Specialty chemicals company LANXESS is launching Cosmelin, a new line of high-performance, readily biodegradable esters for the cosmetics and personal care industry. The products are aimed at manufacturers of skin and hair care, sun care, and decorative cosmetics.

Formulation flexibility

The Cosmelin range of readily biodegradable esters offers a large formulation flexibility. They were developed to deliver premium sensory performance in both silicone-containing and silicone-free formulations. In the latter case, they can be used as a high-performance alternative to silicone.

Readily biodegradable

The range of Cosmelin esters meets the requirements of the OECD 301 standard for ready biodegradability and serves as a functional substitute for cyclomethicone and dimethicone – classic silicone compounds widely used in cosmetics. Compared to these, the esters degrade significantly faster and more completely in the environment after use.

“With the Cosmelin esters LANXESS is addressing the growing demand for clean beauty products and eco-friendly ingredients without compromising the skin-feel and performance that consumers expect from premium cosmetic products” says Vince Patram, Head of Global Marketing Lubricant Additives at LANXESS.

Large sensory range and versatile use

Another advantage of the Cosmelin product line is its extensive sensory range: The esters cover the spectrum from very light, fast-spreading textures to rich, film-forming formulations. Designed for low irritation and low comedogenicity, the product range is suitable for sensitive skin formulations. This versatility enables its use across skincare, sun care, haircare, and color cosmetics applications.

Key applications

In skin care, the Cosmelin esters provide breathable moisturization without heaviness or occlusion, offering versatile skin textures including silky, powdery and plush feels while enhancing skin hydration and supporting the skin barrier.

For sun care, Cosmelin provides strong solvency for organic UV filters, forming water resistant, lightweight and non-whitening protective films.

In color cosmetics, its excellent wetting, pigment dispersion and color payoff ensure smooth, adherent application, enabling both glossy and matte finishes as required.

For hair care, it reduces friction, improves smoothness and imparts natural shine without greasiness, helping repair and smooth hair cuticles.

Broad product portfolio

The Cosmelin portfolio includes a range of monoester, diester, polyol ester and trimellitate products to meet diverse texture requirements, from light and dry to rich and silky. Cosmelin 5131 (Isononyl Isononanoate) features an ultra-light, powdery skin feel. Cosmelin 5145 (Cetyl Ethylhexanoate) delivers a rich, silky glass skin finish for formulations, while Cosmelin 5141 (Triisotridecyl Trimellitate) provides high gloss and long lasting makeup performance.

Looking ahead, LANXESS will continue to expand its Cosmelin product portfolio to meet the diversified market demand for sustainable beauty ingredients. The Cosmelin product line complements LANXESS’ portfolio for home and personal care products with preservatives as well as fragrance chemicals.

Detailed information on Cosmelin can be found at https://lanxess.com/en/products/brands/cosmelin.

About LANXESS

LANXESS is a leading specialty chemicals company with sales of EUR 5.7 billion in 2025. The company currently has about 11,500 employees in 32 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives and consumer protection products. LANXESS has achieved leading positions in the Dow Jones Best-in-Class Index and the MSCI ESG and ISS ESG ratings, among others, for its commitment to sustainability.

Forward-Looking Statements

Forward-Looking StatementsThis company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

Download

Information for editors: All LANXESS news releases and their accompanying photos can be found at http://press.lanxess.com. Recent photos of the Board of Management and other LANXESS image material are available at http://photos.lanxess.com.

You can find further information concerning LANXESS chemistry at http://lanxess.com/en/Media/Stories.

FOLLOW US

  • Rely+On Medero: highly effective against bacteria, mycobacteria, fungi, bacterial spores, viruses, and yeasts

  • Rely+On portfolio for effective infection prevention and control in the healthcare sector

  • LANXESS booth: Messe Düsseldorf, Hall 11, No. E36

CologneOctober 22, 2026

LANXESS

LANXESS will be unveiling its new, high-level disinfectant Rely+On Medero for the first time at Medica 2026

At the Medica 2026 medical trade fair, taking place November 16–19, LANXESS will present its Rely+On product portfolio for infection prevention in the healthcare sector, as well as its selection of active ingredients for the formulation of disinfectants.

The highlight of the exhibition will be the premiere of Rely+On Medero, a new broad-spectrum disinfectant. It is highly effective against bacteria, mycobacteria, fungi, bacterial spores, viruses, and yeasts. It works reliably within minutes, even against stubborn biofilms of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA). The disinfectant’s chemistry is based on the active oxygen Potassium Monopersulfate (Oxone) as well as in-situ generated active chlorine. As a result, it does not induce acquired resistance—not even in MRSA.

Disinfectant for medical devices and hard surfaces

Rely+On Medero is suitable for devices classified as non-invasive medical devices, as well as for hard surfaces in medical practices and hospitals, including intensive care units and isolation rooms. Rely+On Medero is approved as a disinfectant for medical devices and thus falls under Class IIa of the European Union’s Medical Devices Regulation. For the disinfection of non-medical hard surfaces, Rely+On Medero is authorised as Product Type II under the Biocidal Products Regulation.

Rely+On product portfolio against antibiotic resistance

With the Rely+On product portfolio, LANXESS is committed to scientifically sound disinfection solutions in the fight against antibiotic resistance. These include Rely+On Virkon, a well-established broad-spectrum disinfectant for hospitals, medical laboratories, and public health facilities, as well as Rely+On PeraSafe, a product for the safe and rapid decontamination of medical instruments.

Both products comply with international standards and have proven their effectiveness in efficacy tests conducted in accordance with European standards. Rely+On has proven to be effective in emergency scenarios such as the spread of SARS-CoV-2, avian influenza, noroviruses, and other pathogens.

Global use in healthcare and the public sector

LANXESS has specifically designed the Rely+On products to meet the ever-changing requirements of the healthcare sector and the public sector. Healthcare facilities use Rely+On solutions for emergency prevention as well as to contain potential outbreaks of infection.

LANXESS will be providing information about the Rely+On products, their performance, and their wide range of applications at Medica 2026 in Hall 11, Booth E36. Information on Rely+On products and their applications is also available at ▷ Rely+On® | Infection Control Products | LANXESS

Use biocidal products with care. Always read the label and product information before use.

About LANXESS

LANXESS is a leading specialty chemicals company with sales of EUR 5.7 billion in 2025. The company currently has about 11,500 employees in 32 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives and consumer protection products. LANXESS has achieved leading positions in the Dow Jones Best-in-Class Index and the MSCI ESG and ISS ESG ratings, among others, for its commitment to sustainability.

Forward-Looking Statements

Forward-Looking StatementsThis company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

Download

Information for editors: All LANXESS news releases and their accompanying photos can be found at http://press.lanxess.com. Recent photos of the Board of Management and other LANXESS image material are available at http://photos.lanxess.com.

You can find further information concerning LANXESS chemistry at http://lanxess.com/en/Media/Stories.

FOLLOW US

LANXESS launches highly effective disinfectant for the medical sector Bull 2 Bear 0 Product/operations
  • Rely+On Medero is effective against bacteria, mycobacteria, fungi, bacterial spores, viruses, and yeasts

  • Does not induce acquired resistance on bacteria and yeast

  • Approved as a medical device disinfectant

CologneOctober 20, 2026

Packshot Rely+On® MederoLANXESS

LANXESS offers Rely+On Medero in 20- or 40-gram sachets as well as in 1 kilo or 5 kilo units

Specialty chemicals company LANXESS is launching Rely+On Medero, a new disinfectant for the medical sector. It is highly effective against bacteria, bacterial spores—including Clostridioides difficile (C. difficile)—viruses, yeasts, and mycobacteria such as tuberculosis. Even against difficult biofilms of Pseudomonas aeruginosa and Staphylococcus aureus it works reliably within a few minutes.

No resistance development

The chemistry of the disinfectant is based on the active oxygen Potassium monopersulfate (Oxone) and on active chlorine generated in-situ. It does not induce acquired resistance, not even in MRSA (methicillin-resistant Staphylococcus aureus) or VRE (vancomycin-resistant enterococci). This is a decisive advantage compared to active ingredients such as quaternary ammonium compounds, or aldehydes.

Disinfection of surfaces and non-invasive medical devices

The disinfectant is suitable for equipment classed as non-invasive medical devices and for hard surfaces and other types of surfaces in medical practices and hospitals, including wards and intensive care units, operating theatres, and isolation rooms.

The product is available as a powder, and is readily dissolved in water for use. It retains its full spectrum of efficacy from the time the solution is prepared until the end of its shelf life.

Approval as a disinfectant for medical devices

Rely+On Medero is approved as a disinfectant for medical devices and is therefore classified as a Class IIa device under the European Union’s Medical Device Regulation. For non-medical hard surface disinfection Rely+On Medero will be registered under Biocidal Products Regulation Product Type II.

Easy to use and dose

The product is low-odor during use, especially compared to other formulations based on hypochlorite, also known as bleach. Without the typical, pungent disinfectant odor, it can also be used in occupied patient areas. The disinfectant is compatible with materials such as stainless steel, polyethylene, and polycarbonate, making it suitable for use on medical devices and surfaces.

LANXESS offers Rely+On Medero in different packaging sizes: The single-dose format in 20- or 40-gram sachets allows the product to be dosed easily and is supported by a clear dosing table. The product is also available in 1 kilo or 5 kilo units.

Distribution in Europe, Asia, and South America

LANXESS aims to start distributing Rely+On Medero in many countries globally.

The product rounds out the Rely+On product line, which includes Rely+On Virkon for routine disinfection and Rely+On PeraSafe for high level disinfecting temperature-sensitive devices such as endoscopes.

For commercial inquiries, questions about product samples, or technical documentation regarding Rely+On Medero, LANXESS representatives are available at [email protected]. More information can be found on the website: medero.lanxess.com

Use biocides safely. Always read the label and product information before use.

About LANXESS

LANXESS is a leading specialty chemicals company with sales of EUR 5.7 billion in 2025. The company currently has about 11,500 employees in 32 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives and consumer protection products. LANXESS has achieved leading positions in the Dow Jones Best-in-Class Index and the MSCI ESG and ISS ESG ratings, among others, for its commitment to sustainability.

Forward-Looking Statements

Forward-Looking StatementsThis company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

Download

Information for editors: All LANXESS news releases and their accompanying photos can be found at http://press.lanxess.com. Recent photos of the Board of Management and other LANXESS image material are available at http://photos.lanxess.com.

You can find further information concerning LANXESS chemistry at http://lanxess.com/en/Media/Stories.

FOLLOW US

Prompts

LANXESS Aktiengesellschaft (ticker LXS), listed in Germany.

ETFs Holding LANXESS Aktiengesellschaft

ETF Weight in ETF Shares Market value As of
AVDV 0.23% 3,074,183 $ 44.105M Nov 16, 2026
DISV 0.08% 272,408 $ 3.979M Nov 12, 2026
DFIS 0.05% 186,818 $ 2.729M Nov 12, 2026
AVDS 0.03% 8,034 $ 115.263K Nov 16, 2026
DXIV 0.03% 4,756 $ 69.474K Nov 12, 2026
AVDE 0.02% 329,472 $ 4.727M Nov 16, 2026
AVSD 0.02% 4,018 $ 57.646K Nov 16, 2026
DFSI 0.01% 5,992 $ 87.53K Nov 12, 2026
DFAI 0.01% 67,077 $ 979.844K Nov 12, 2026
DFIC 0.00% 35,813 $ 523.147K Nov 12, 2026
DFAX 0.00% 10,224 $ 149.35K Nov 12, 2026